(ASTM)


NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.000.00 (0.00%)
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open0.00
Prev Close0.00
Bid0.00 x
Ask0.00 x
Day's Range0.00 - 0.00
52wk Range
1y Target EstN/A
Market CapN/A
P/E Ratio (ttm)N/A
BetaN/A
Volume0
Avg Vol (3m)N/A
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • American City Business Journals5 months ago

    ​Last month’s big stock spike at Vericel cut in half by further trial data

    Over the last month, shares of Cambridge-based Vericel Corp. have spiked to their highest levels in more than two years on the strength of a cell therapy treatment for advanced heart failure. Formed in 2014 by the purchase of Genzyme’s cell therapy products by Michigan-based Aastrom Biosciences, Vericel (VCEL) today announced the publication of the 114-patient, Phase 2b trial in the journal, The Lancet, following a presentation of that data at a conference in Chicago. The newly-disclosed data backs up the previously-announced results showing that the treatment called ixmyelocel-T met its primary endpoint of reducing the total number of deaths, cardiovascular hospitalizations, and unplanned outpatient and emergency visits compared to placebo over the course of a year after administration in patients whose hearts have an enlarged and weakened left ventricle (the heart’s main pumping chamber).

  • American City Business Journals6 months ago

    ​Cambridge-based Vericel doubles in value on heart failure trial results

    The market value of a Cambridge company that bought the cell therapy business from Sanofi Genzyme two years ago, called Vericel, doubled this morning after the firm said a mid-stage trial of a treatment for heart failure hit its goals. Vericel (VCEL), which has about 200 employees and is headquartered on Sidney Street, saw its shares rise 113 percent to $4.49 as of 11:50 a.m. today, giving it a market capitalization of $106 million. The company is a new incarnation of a 25-year-old, Ann Arbor, Michigan-based biotech called Aastrom Biosciences, which purchased the assets from Genzyme (SNY) in 2014.

  • Marketwired2 years ago

    Aastrom Biosciences Changes Name to Vericel Corporation

    Aastrom Biosciences, Inc. , a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the change of its corporate name to ...